The present invention relates to the field of molecular biochemistry and medicine, and in particular to ligands comprising modified amino acid residues, targeting the amyloid-β peptide associated with Alzheimers disease for prevention of aggregation, neurotoxicity and use thereof as drugs for treatment of Alzheimers disease.